Skip to navigation Skip to content



Further Data from Phase 2 Statins Trial in Progressive MS Show Effect on Cognition: Phase 3 Study Underway

June 9, 2017

New data have been published from a completed phase 2 study of the cholesterol-lowering drug simvastatin in people with secondary progressive MS, indicating improvements in some aspects of cognitive function after 2 years among those given simvastatin. Previously reported results suggested that simvastatin reduced the rate of brain atrophy, or shrinkage.  A large phase 3 trial of simvastatin is underway, with co-funding from the National MS Society and others, being led by Dr. Jeremy Chataway (University College London).

Read more on the website of University College London Hospitals

Read the scientific paper, and the accompanying editorial

Read more about the phase 3 statins trial


About Multiple Sclerosis

Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS.


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.